Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP
Published Date: 1/29/2026
Proposed Rule
Summary
The government wants your thoughts on updating rules that stop sneaky deals and freebies in Medicare and state health programs, especially for new drug sales like those on TrumpRx. This could change how drug companies sell directly to patients, making meds fairer and cheaper for Americans. Speak up by March 30, 2026, to help shape these important changes that could save money and protect patients.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
TrumpRx: Direct-to-Consumer Drug Platform
HHS is establishing TrumpRx, a platform to let American patients buy prescription drugs directly from manufacturers at a “Most‑Favored‑Nation” price, bypassing middlemen. HHS says removing government obstacles to ensure access to affordable prescription drugs through TrumpRx is a key priority and is seeking public input through this request for information.
Potential Changes to Anti‑Kickback Safe Harbors
The OIG is asking whether to modify or add safe harbors to the Federal anti‑kickback statute (42 CFR 1001.952) and exceptions to the Beneficiary Inducements CMP (42 CFR 1003.110) to support direct‑to‑consumer manufacturer drug sales while protecting against fraud and abuse. The agency requests public comment by March 30, 2026.
Safe Harbor for Personal Services/Management Contracts
The RFI notes that existing safe harbors relevant to direct‑to‑consumer programs may include the personal services and management contracts safe harbor (42 CFR 1001.952(d)) and asks for input on conditions that should be included in any new or modified safe harbor.
Guidance vs Regulation for DTC Sales
OIG is asking whether clarifying guidance (for example, an amended Special Advisory Bulletin, FAQs, or other guidance) might be sufficient instead of new regulations to address direct‑to‑consumer sales to people covered by Federal health care programs. The RFI seeks examples and feedback and sets a comment deadline of March 30, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17622, Federal Independent Dispute Resolution Operations; Correction
This document corrects typographical errors and omissions in the final rule that appeared in the June 4, 2026, Federal Register titled "Federal Independent Dispute Resolution Operations" (referred to hereafter as the "IDR final rule"). The effective date of the IDR final rule was August 3, 2026.
2026-16414, Adoption and Foster Care Analysis and Reporting System
This document withdraws a proposed rule that was published in the Federal Register on January 11, 2008. The proposed rule would have amended the Adoption and Foster Care Analysis and Reporting System (AFCARS) regulations at 45 CFR 1355.40 and the appendices to Part 1355 to modify the requirements for States to collect and report data to ACF on children in out-of-home care and in subsidized adoption or guardianship arrangements with the State. This document also withdraws the provision of the 2008 proposed rule that implemented the AFCARS penalty requirements of the Adoption Promotion Act of 2003 (Pub. L. 108-145).
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-16134, Reducing Federal Burden for Head Start Programs
This NPRM proposes to rescind and replace the Head Start Program Performance Standards (Performance Standards), last revised in 2024. The proposed Performance Standards would significantly reduce Federal bureaucratic burden on programs; defer to State policies wherever possible; return substantial local control to Head Start agencies delivering the services and to parents as the primary caregivers and decision-makers for their children; reduce unnecessary duplication of Head Start regulations with Federal statute and other regulations; and emphasize the critical role of health, nutrition, and physical exercise for young children.
2026-15686, Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements
This final rule updates the hospice wage index, payment rates, and aggregate cap amount for fiscal year 2027. This final rule also includes an analysis of Medicare non-hospice spending, including details regarding a hospice service and spending variation index, and finalizes the requirement that hospices provide the hospice election statement addendum to all Medicare beneficiaries at the time of hospice election. Additionally, this rule finalizes conforming changes to discharge from hospice care regulations and changes to the face-to-face encounter regulations. This final rule also includes a summary of comments received on our requests for information regarding community- based palliative care; the construction of a hospice specific wage index; and the overlap between hospice and medical aid in dying laws. Finally, this rule finalizes changes to the Hospice Quality Reporting Program.
2026-15652, Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program
This final rule updates the prospective payment rates for inpatient rehabilitation facilities (IRFs) for Federal fiscal year (FY) 2027. As required by statute, this final rule includes the classification and weighting factors for the IRF prospective payment system's (PPS) case-mix groups and a description of the methodologies and data used in computing the prospective payment rates for FY 2027. It also finalizes the third and final of the 3-year phaseout of the rural adjustment, which began in FY 2025. This final rule includes a solicitation for public comments on alternative data sources for the IRF PPS wage index; requires all therapy treatments and/or therapy evaluations to begin no later than 36 hours from midnight on the day of admission; finalizes requirements for the initial Interdisciplinary Team meeting to occur on or before 4 days from the date the patient is admitted; and summarizes a request for information on potential future IRF PPS payment reform. Additionally, this final rule includes updates to the IRF Quality Reporting Program and changes to the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program.
Previous / Next Documents
Previous: 2026-01807, Notice of Availability and Request for Comment: Revision to the Voluntary Standard for Infant and Cradle Swings
The Consumer Product Safety Commission wants your thoughts on updates to the safety rules for infant and cradle swings. These changes could make swings safer for babies and affect manufacturers and parents. You’ve got until February 12, 2026, to share your opinion—no cost changes announced yet, just safer swings ahead!
Next: 2026-01833, Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage
This new rule updates the rules for Organ Procurement Organizations (OPOs) that help collect and share organs for transplants. It adds clearer guidelines, new quality checks, and updates how OPOs compete and appeal decisions to boost organ donations and save more lives. OPOs and transplant patients will feel the impact, with comments open until March 31, 2026, and no new costs announced yet.